carbapenems | CMAC

carbapenems

Wound Infections: a Role of Microbiological Monitoring for the Hospital Antimicrobial Policy

During the last 7 years the leading pathogens in the etiology of skin and soft tissue infections in the hospital were Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli and Pseudomonas аeruginosа. Statistical prognosis does not suggest …

Hospital-Acquired Pneumonia in Patients with Hematological Malignancies in an ICU

Objective. To determine causative agents of hospitalacquired pneumonia (HAP), their incidence rates, and susceptibility to antimicrobial agents in patients with hematological malignancies in an intensive care unit (ICU). Materials and Methods. Broncho-alveolar lavage (BAL) specimens obtained from oncohaematologic patients with pneumonia hospitalized to the ICU between December 2009 and December 2010 were retrospectively studied. Results. A total of 142 BAL specimens were obtained from 72 hospitalized patients aged of 19 to 86 years.

Carbapenem-Resistant Pseudomonas aeruginosa Isolated in Perm City Hospitals

Analysis of susceptibility to carbapenems of P. aeruginosa (n=178) isolated in different Perm city hospitals showed that the majority of carbapenem-resistant strains were obtained from intensive care units (ICU) patients in surgical hospitals. The …

Ertapenem – a Newer Carbapenem

The carbapenems are class of beta-lactam antibiotics with exceptionally wide spectrum of activity, beneficial pharmacokinetic parameters and low toxicity as well. Such agents as imipenem and meropenem have already been succesfully used for a long …

Doripenem: a New Carbapenem Antimicrobial

There is a clinical need for newer effective antimicrobials that would overcome resistance mechanisms across a wide range of microorganisms. Doripenem is a novel promising carbapenem antimicrobial, which was approved by Food and Drug Administration …

Use of Carbapenems in Clinical Practice: When, Which and How Long?

Carpabenems (imipenem, meropenem, ertapenem) are currently one of the antibiotic classes that exhibit the broadest spectrum of activity and characterized by the low resistance rates of clinically significant pathogens. This article is an attempt to …

Carbapenems: Myths and Reality

This paper presents analysis of microbiological, clinical and pharmacoeconomic studies of carbapenems. Use of carbapenems during the last two decades was not associated with emergence of resistance to these agents among clinically significant human …